MUSC Foundation for Research Development Patent applications |
Patent application number | Title | Published |
20150342647 | SKELETAL BONE FIXATION MECHANISM - A skeletal fixation apparatus may include two or more bodies that are attached to two or more screws that have been inserted into vertebral bodies associated with a patient. The apparatus may also include two or more cylindrical members that are attached to the bodies to control the movement or alignment of the bodies when the skeletal fixation apparatus is being installed in the patient. The apparatus may further include a rod that includes a first curvature and a second curvature. The first curvature may be different than the second curvature and may be based on a medical diagnosis associated with stabilizing the vertebral bodies. The second curvature may enable the bodies to be immovably fastened to the rod in a manner that precludes the cylindrical members from contacting each other or causing a false torque condition to exist when the skeletal fixation apparatus is installed in the patient. | 12-03-2015 |
20150259669 | MICROBIAL ELECTROSYNTHETIC CELLS - Methods are provided for microbial electrosynthesis of H | 09-17-2015 |
20150174196 | COMPOSITIONS AND METHODS FOR WOUND HEALING AND TISSUE REPAIR - Provided are peptides that can inhibit collagen synthesis, processing and/or secretion from scar forming cells or fibroblasts. Also provided are methods for using the peptides to produce an anti-fibrotic, anti-scarring, anti-inflammatory, and/or pro-regenerative effect, e.g., on an injured or diseased tissue. | 06-25-2015 |
20150105345 | USES OF ANTAGONISTS OF HYALURONAN SIGNALING - Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer. | 04-16-2015 |
20150065434 | CYCLIC PEPTIDE INHIBITORS OF LYSINE-SPECIFIC DEMETHYLASE 1 - Provided herein are cyclic peptide inhibitors of lysine-specific demethylase 1. These cyclic peptides have the potential to treat cancer, diabetes, cardiovascular disease, and neurological disorders. | 03-05-2015 |
20150057247 | PYRAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS - Provided herein are compounds of the formula (I): | 02-26-2015 |
20150039034 | SKELETAL BONE FIXATION MECHANISM - A skeletal fixation apparatus may include two or more bodies that are attached to two or more screws that have been inserted into vertebral bodies associated with a patient. The apparatus may also include two or more cylindrical members that are attached to the bodies to control the movement or alignment of the bodies when the skeletal fixation apparatus is being installed in the patient. The apparatus may further include a rod that includes a first curvature and a second curvature. The first curvature may be different than the second curvature and may be based on a medical diagnosis associated with stabilizing the vertebral bodies. The second curvature may enable the bodies to be immovably fastened to the rod in a manner that precludes the cylindrical members from contacting each other or causing a false torque condition to exist when the skeletal fixation apparatus is installed in the patient. | 02-05-2015 |
20140349944 | CHAPERONE-BASED INTEGRIN INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES - The present disclosure provides isolated integrin αL polypeptides, such as α7 helix polypeptides from the alpha I domain of integrin. Such polypeptides inhibit the interaction between integrin and gp96, thereby inhibiting gp96 activity. Such inhibition can be used to prevent cancer cell growth, cancer metastasis and/or inflammation. | 11-27-2014 |
20140275492 | HUMAN MONOCLONAL ANTIBODIES AND METHODS FOR PRODUCING THE SAME - The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer. | 09-18-2014 |
20140275178 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS - Provided herein are compounds of the formula (I): | 09-18-2014 |
20140275075 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS - Provided herein are compounds of the formula (I): | 09-18-2014 |
20140230821 | VENTILATION DEVICES AND METHODS OF USE - Provided are systems, devices and methods for ventilating patients. For example, provided are ventilation masks. The described ventilation masks can be used in ventilation procedures of patients. | 08-21-2014 |
20140154307 | INHIBITION OF FACTOR B, THE ALTERNATIVE COMPLEMENT PATHWAY AND METHODS RELATED THERETO - Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway. | 06-05-2014 |
20140113962 | INHIBITORS OF NITRIC OXIDE SYNTHASE - The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP. | 04-24-2014 |
20140093974 | METHODS FOR ASSESSING MODIFIED LDL IMMUNE COMPLEXES IN SUBJECTS HAVING OR AT RISK OF CORONARY ARTERY DISEASE - The present invention relates to the analysis of modified LDL in the context of immune complexes. In particular, ox-LDL and AGE-LDL are shown to predict the development of coronary artery disease and other micro- and macrovascular disorders, particularly in the context of diabetes. | 04-03-2014 |
20140073572 | TARGETING COMPLEMENT FACTOR H FOR TREATMENT OF DISEASES - The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion. | 03-13-2014 |
20140050375 | SYSTEMS AND METHODS FOR IMAGE GUIDED SURGERY - Systems and methods for image guided surgery are disclosed herein. An example method can include: receiving a plurality of 2D projection images of an object at a plurality of projection angles during a first period of time; and receiving a position of an instrument relative to a tracking coordinate system during the first period of time. The method can also include registering the plurality of 2D projection images relative to the tracking coordinate system to obtain a transformation function that defines a relationship between a coordinate system of the plurality of 2D projection images and the tracking coordinate system; receiving an adjusted position of the instrument relative to the tracking coordinate system during a second period of time that is subsequent to the first period of time; and estimating an adjusted position of the instrument relative to the plurality of 2D projection images using the transformation function. | 02-20-2014 |
20140038203 | METHODS FOR DETECTING OR PREDICTING KIDNEY DISEASE - Methods of detecting or predicting the onset or magnitude of kidney diseases such as acute kidney disease (AKI), previously called acute renal failure (ARF), are provided. In various aspects, methods and kits are provided to detect specific urinary proteins associated with AKI diagnosis or prognosis such as, e.g., angiotensinogen. | 02-06-2014 |
20140037705 | NOVEL BACTERIOSTATIC AND ANTI-COLLAGENOLYTIC DENTAL MATERIALS THROUGH THE INCORPORATION OF POLYACRYLIC ACID MODIFIED CuQ NANOPARTICLES - Provided are antibacterial and antimicrobial surface coatings and dental materials by utilizing the antimicrobial properties of copper chalcogenide and/or copper halide (CuQ, where Q=chalcogens including oxygen, or halogens, or nothing). An antimicrobial barrier is created by incorporation of CuQ nanoparticles of an appropriate size and at a concentration necessary and sufficient to create a unique bioelectrical environment. The unique bioelectrical environment results in biocidal effectiveness through a multi-factorial mechanism comprising a combination of the intrinsic quantum flux of copper (Cu | 02-06-2014 |
20140024677 | METHODS FOR INDUCING MITOCHONDRIAL BIOGENESIS - Methods and compositions for inducing mitochondrial biogenesis are provided. In some aspects, methods for the treatment of diseases such as acute kidney disease (AKI) or a muscle wasting disease by administering tomoxetine, nisoxetine, fenoterol, formoterol, or procaterol to an individual are provided. | 01-23-2014 |
20130274206 | Compositions and Methods for Promoting Wound Healing and Tissue Regeneration - Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject. | 10-17-2013 |
20130217632 | Non-Natural Amino Acids - This invention relates in one aspect to non-natural desamino alkyl amino acid compounds, methods of making these compounds, and peptides containing these compounds. In one embodiment, the peptide is neurotensin (8-13) in which the N-terminus is an alpha-desamino, alpha-methyl-N,N-dimethyl-homolysine residue of the invention. | 08-22-2013 |
20130177628 | COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION - Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject. | 07-11-2013 |
20130115674 | Human Monoclonal Antibodies to Human Nucleolin - The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysi-ology of the disease. | 05-09-2013 |
20130089496 | TUMOR TARGETED ANTIBODIES AND METHOD FOR USING THE SAME - Isolated and recombinant antibodies, such as EGFR-binding antibodies. Antibodies can comprising the sequence of an immunoglobulin heavy constant gamma-1 region encoded by a human G1M3 allele. For example, antibodies of the embodiments can comprise an immunoglobulin heavy constant gamma-1 region wherein position 214 is arginine; position 356 is glutamic acid; position 358 is methionine and/or position 431 is alanine. Methods for treating diseases, such as cancer, in a human subject with such antibodies are also provided. | 04-11-2013 |
20120288938 | SELF-ASSEMBLING CELL AGGREGATES AND METHODS OF MAKING ENGINEERED TISSUE USING THE SAME - A composition comprising a plurality of cell aggregates for use in producing engineered organotypic tissue by organ printing. A method of making a plurality of cell aggregates comprises centrifuging a cell suspension, extruding the resulting pellet through an orifice, and cutting the extruded pellet into pieces. Apparatus for making cell aggregates comprises an extrusion system and a cutting system. In a method of organ printing, a plurality of cell aggregates are embedded in a polymeric or gel matrix and allowed to fuse to form a desired three-dimensional tissue structure. An intermediate product comprises at least one layer of matrix and a plurality of cell aggregates embedded therein in a predetermined pattern. Modeling methods predict the structural evolution of fusing cell aggregates for combinations of cell type, matrix, and embedding patterns to enable selection of organ printing process parameters for use in producing an engineered tissue having a desired three-dimensional structure. | 11-15-2012 |
20120122870 | Treatment Of Ischemia-Reperfusion Injury - Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no clinically proven strategies that prevent acute renal failure following cardiac surgery. The present invention provides a variety of methods for the treatment or prevention of ischemia-reperfusion injury. In one aspect of the invention, a method for treating or preventing ischemia-reperfusion injury includes administering to a subject an effective amount of a sphingosine kinase inhibitor. Sphingosine kinase inhibitors are very effective in the protection against IR-induced acute renal failure and liver failure. Moreover, the effects occur very early after administration, requiring only a very short time of treatment. Toxicology studies with sphingosine kinase inhibitors demonstrate that they have low toxicity, even in long-term treatment. | 05-17-2012 |
20120022343 | SYSTEMS AND METHODS FOR DETECTING DECEPTION BY MEASURING BRAIN ACTIVITY - Methods for determining whether the brain activity of a human subject in response to a stimulus of interest or question of interest is characteristic of a state of interest, such as a deceptive state or a truthful state, are disclosed. Some methods include the use of control questions, including truthful control questions and deceptive control questions, to provide bases for comparison for responses to stimuli of interest or questions of interest. In some methods, brain maps are generated and compared. Also disclosed are systems for detecting deception by measuring brain activity. | 01-26-2012 |
20120015872 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
20120015871 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
20120014952 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
20120010094 | DETECTING AND MONITORING LEFT VENTRICULAR HYPERTROPHY AND CONGESTIVE HEART FAILURE BY PROFILING BIOMARKERS - Disclosed herein are methods of detecting, monitoring, and predicting left ventricular hypertrophy, congestive heart failure and related conditions by profiling biomarkers. | 01-12-2012 |
20110318758 | HUMAN MONOCLONAL ANTIBODIES AND METHODS FOR PRODUCING THE SAME - The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer. | 12-29-2011 |
20110264156 | DEVICES AND METHODS FOR TREATMENT OF MYOCARDIAL CONDITIONS - Provided are devices and methods for treating a subject having a myocardial condition using sub-threshold electrical stimulation. | 10-27-2011 |
20110263664 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer - The disclosure relates to inhibitors of Pim-1 and/or Pim-2 protein kinase, to compositions comprising one or more inhibitors of Pim-1 and/or Pim-2 protein kinase, and to methods for treating cancer. | 10-27-2011 |
20110245188 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR CONDITIONS - The present invention relates to methods and compositions of treating or preventing inflammatory diseases or conditions in a patient comprising administering to the patient a therapeutically effective amount of a composition comprising a glutathione donor, 5-amino 4-imidazolecarboxamide ribotide (AICAR), a 3-hydroxy-3-methylgluatryl-coenzymeA (HMG-CoA) reductase inhibitor, D-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol HCl (D-PDMP), and/or 1,5-(butylimino)-1,5-dideoxy-D-glucitol (Miglustat), or derivatives thereof. | 10-06-2011 |
20110237662 | Use of Statins to Inhibit Inflammation and Vascular Disease - The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP. | 09-29-2011 |
20110117560 | ASSESSING LEFT VENTRICULAR REMODELING VIA TEMPORAL DETECTION AND MEASUREMENT OF microRNA IN BODY FLUIDS - Disclosed are methods and materials for assessing cardiac failure, cardiac hypertrophy, and left ventricular remodeling using microRNA levels. The level of microRNAs can be measured in a body fluid, such as plasma and serum. | 05-19-2011 |
20110059173 | COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION - Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject. | 03-10-2011 |
20110034419 | Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease - Disclosed are methods of diagnosing cardiovascular disease comprising measuring sphingolipids. Also disclosed are methods of predicting cardiovascular disease comprising measuring sphingolipids. Also disclosed are methods of identifying subjects at risk of developing cardiovascular disease comprising measuring sphingolipids. | 02-10-2011 |
20100291188 | Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same - We claim the compositions of matter and methods described herein. | 11-18-2010 |
20100286762 | Compositions and Methods for Ameliorating Clinical Electrical Disturbances - Disclosed are compositions and methods for the use of ACT1 peptide or other approaches to targeting the ZO-1 PDZ2 domain to treat non-injury related disturbance to electrical activation and ion transients in organ systems. | 11-11-2010 |
20100015651 | Predicting Heart Failure Following Myocardial Infarction by Protease and Protease Inhibitor Profiling - Disclosed herein are methods of detecting or predicting diastolic heart failure in a subject, comprising identifying a profile of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) from a body fluid of the subject that is associated herein with the existence of likely development of left ventricular dilation (LVD). | 01-21-2010 |
20090192120 | INHIBITORS OF NITRIC OXIDE SYNTHASE - The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP. | 07-30-2009 |
20090111812 | METHODS FOR TREATING INFLAMMATORY DISORDERS - The present invention relates generally to the fields of molecular biology. More particularly, it concerns materials and methods for the treatment of nitric oxide and cytokind mediated disorders. In a preferred embodiment, PDMP may be used to inhibit the expression of iNOS and pro-inflammatory cytokines such as TNFα and IL1β. | 04-30-2009 |
20080275104 | METHODS OF TREATING JUVENILE TYPE 1 DIABETES MELLITUS - The present disclosure describes methods for treating Type 1 diabetes mellitus in juveniles. This treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such as a statin. | 11-06-2008 |
20080233563 | Enhanced Detection of Rna Using a Panel of Truncated Gene-Specific Primers for Reverse Transcription - The present invention provides truncated gene-specific primers in panels that can be used during the reverse transcription step of RT-PCR to increase signal detection of cancer gene markers in a tissue sample. Also provided are forward and reverse primers for RT-PCR. Methods of using the primers are also provided. | 09-25-2008 |
20080227846 | METHODS OF TREATING JUVENILE TYPE 1 DIABETES MELLITUS - The present disclosure describes methods for treating or preventing Type 1 diabetes mellitus in juveniles, particularly in juveniles newly diagnosed with Type 1 diabetes. This prevention or treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such as a statin, thereby decreasing the destruction of islet cells, or maintaining endogenous insulin production, in the juvenile. | 09-18-2008 |